TICKERNERD
Menu
CDIOCDIOHealthcare · Biotechnology

CDIO Stock Forecast: Cardio Diagnostics Holdings, Inc. Price Predictions for 2026-2027

Last close, 15 Sept 2026
$2.00
−3.38% on the day

Ticker Nerd's systematic factor model, run across ~4,600 US stocks, ranks it 20 of 100 as at 14 Sept 2026 — in the weakest quartile.

Market cap
$6.0M
Ticker Nerd rank
20 / 100
Median analyst target
—
Analysts covering
1
Revenue$5K−28.3% y/y
Operating income−$1.5M
Net income−$1.5M
Free cash flow−$1.4M
Quarterly, 8 quarters to 30 June 2026 · latest quarter's figure shown
Total return, dividends reinvested
1W
+2.0%
1M
−2.0%
YTD
−26.2%
1Y
−46.7%
From 52W high
−69.5%
From 52W low
+90.5%
$1.05
$6.55
52-week range, adjusted closes · the dot is the last close
Ticker Nerd rank

CDIO stock analysis: one number for the whole business

Consensus tells you what everyone already believes. The model scores Cardio Diagnostics Holdings, Inc. on its factor families — the same systematic rank behind the Ticker Nerd portfolio.

Where the model ranks itAs at 14 Sept 2026
20 / 100

Percentile across ~4,600 US stocks on Ticker Nerd’s systematic factor model. Higher is better. How the model is built and tested

Size
95
Accruals
75
Issuance
48
Quality
38
Growth
30
Revisions
25
Volatility
9
Momentum
8
Value
6

Size (95): Smaller than most of the companies we track.

Value (6): The shares cost a lot relative to the profits and assets behind them.

Built and run by Aslam Ghouse, an ex-Goldman Sachs quant trader with fourteen years in markets.

Wall Street

CDIO stock forecast 2026-2027: analyst price targets & predictions

The bullish and bearish analyst opinions on CDIO, reported as data — targets and ratings, the market's view beside the model's.

Share price and the analyst range, 12 monthsAdjusted close, US dollars
$1.00$2.00$3.00$4.00$5.00Oct 25Jan 26Apr 26Jul 26CDIO

Price targets and ratings are third-party analyst estimates, reported here as data. They are not Ticker Nerd forecasts, and they are frequently wrong.

Data provided by Twelve Data

What Wall Street says1 analysts
1 Buy0 Hold0 Sell
Recent analyst actionsNewest first
DateFirmActionRatingTarget
27 Aug 2024BenchmarkReiteratesSpeculative Buy$2.00
6 June 2024BenchmarkMaintainsSpeculative Buy—
19 Apr 2024BenchmarkMaintainsSpeculative Buy—
15 June 2023BenchmarkReiteratesSpeculative Buy—
22 May 2023Northland Capital MarketsInitiatesOutperform—
18 Apr 2023BenchmarkReiteratesSpeculative Buy—

Price targets and ratings are third-party analyst estimates, reported here as data. They are not Ticker Nerd forecasts, and they are frequently wrong.

Market Radar

This page is one stock. Monday covers all of them.

Computed off the Friday close and sent before the US open.

Market Radar reports the week’s largest rank changes across roughly 4,600 US stocks, the factor behind each one, and where the market went. CDIO appears on the weeks it earns a place.

Free, every Monday. Unsubscribe any time.

Performance

CDIO vs the S&P 500

Both lines are total return — dividends reinvested — so the comparison is honest on both sides.

Over the twelve months to 15 Sept 2026, Cardio Diagnostics Holdings, Inc. returned −46.7% against +16.4% for the S&P 500, dividends included.

CDIO vs S&P 500, last 12 monthsTotal return, rebased to 100
20406080100120140Oct 25Jan 26Apr 26Jul 26CDIOS&P 500

Download this chart as an image — free to reuse; link this page as the source.

Data provided by Twelve Data

Estimates

CDIO analyst estimate revisions

Not the forecast itself — the direction analysts are revising it. Revision direction is one of the model's factor families.

Fundamentals

Cardio Diagnostics Holdings, Inc. (CDIO) financial data

A margin means little on its own. Each bar marks where the figure sits across the whole US universe we score.

Valuation
Trailing P/E
−0.5×

Cheaper than 80% of US stocks

Price / sales
415.8×

Cheaper than 2% of US stocks

Price / book
0.8×

Cheaper than 78% of US stocks

EV / EBITDA
−0.1×

Cheaper than 62% of US stocks

Growth & margins
Revenue growth (YoY)
−28.3%

Higher than 9% of US stocks

Earnings growth (YoY)
−28.3%

Higher than 17% of US stocks

Gross margin
—
Operating margin
−27950.5%

Higher than 1% of US stocks

Net margin
0.0%

Higher than 30% of US stocks

Returns & dividend
Return on equity
−75.4%

Higher than 17% of US stocks

Return on assets
−44.1%

Higher than 9% of US stocks

Dividend yield
—

Bars mark the percentile across the ~4,600 US stocks Ticker Nerd covers, among those reporting the figure.

Key statistics

Cardio Diagnostics Holdings, Inc. (CDIO) statistics: revenue, profit & scale

The headline figures, each with its date. Every row carries its own link — cite it straight from here.

  • Cardio Diagnostics Holdings, Inc. has a market value of $6.0M and an enterprise value of $791K.

  • Revenue in the twelve months to 30 June 2026: $14K. The latest quarter shrank 28.3% year on year.

  • Net income over the same four quarters: −$6.5M, a −44771.8% net margin.

  • Free cash flow in the twelve months to 30 June 2026: −$6.1M.

  • Shares outstanding: 3.0M.

  • Trailing P/E: −0.5×; forward P/E: −8.1× — the forward figure prices analyst consensus estimates, not reported earnings.

  • Cardio Diagnostics Holdings, Inc. employs 15 people — $963.3 of revenue per employee.

Statement figures: company filings via Twelve Data, four quarters to 30 June 2026 · market figures as at 14 Sept 2026

Data provided by Twelve Data

Peers

CDIO vs competitors

The nearest names by industry and size, scored by the same model — like for like.

Its peer group, ranked by the same modelBiotechnology
CompanyMarket capTKN rank
CDIOCardio Diagnostics Holdings, Inc.$6.0M
20
KAPAKairos Pharma Ltd.$6.2M
40
LEXXLexaria Bioscience Corp.$5.9M
25
CELZCreative Medical Technology Holdings, Inc.$5.8M
23
CLGNCollPlant Biotechnologies Ltd.$6.6M
34
ENVBEnveric Biosciences, Inc.$6.6M
17
AIMAIM ImmunoTech, Inc.$6.8M
18

Look up any of the roughly 4,600 stocks we score.

The rank is the raw material. Whether the rules would actually own Cardio Diagnostics Holdings, Inc. — and when they’d sell — is the membership. See the Ticker Nerd 20 →

News

Latest CDIO news & analysis

Cardio Diagnostics Report Identifies Growing Rural Cardiovascular Care Gap Amid Ongoing Workforce Shortages and Access Challenges

Business Wire · 26 Aug 2026neutral

Cardio Diagnostics released a new edition of its rural health report, "The State of Rural Hospitals and Cardiovascular Care," which identifies a growing cardiovascular care gap in rural areas amid ongoing workforce shortages and access challenges. The company announced the report release via Business Wire from Chicago.

Why it matters — A CDIO watcher would care because the report highlights underserved rural cardiovascular markets that could be relevant to the company's diagnostic offerings and its positioning within rural healthcare.

Cardio Diagnostics Holdings, Inc. (CDIO) Discusses Precision Molecular Advances and AI for Cardiovascular Disease Detection and Strategic Growth Initiatives Prepared Remarks Transcript

Seeking Alpha · 20 Aug 2026neutral

The news item reports that Cardio Diagnostics Holdings, Inc. (CDIO) discussed precision molecular advances and the use of AI for cardiovascular disease detection, along with strategic growth initiatives, in prepared remarks. This coverage is based on a prepared-remarks transcript published on Seeking Alpha.

Why it matters — A CDIO watcher would care because the prepared remarks outline the company's technology and strategic direction regarding AI-driven cardiovascular detection and growth.

Cardio Diagnostics Begins In-House Test Processing at Its New High Complexity CLIA-Certified Laboratory in Iowa City

Business Wire · 18 Aug 2026positive

Cardio Diagnostics announced it has begun in-house test processing at its newly launched, high-complexity CLIA-certified laboratory in Iowa City, Iowa. The lab is now operational for the company's testing operations.

Why it matters — A CDIO watcher would care because establishing this in-house CLIA-certified laboratory represents a milestone in the company's operational capacity for processing its diagnostic tests.

FAQ

Frequently asked questions about CDIO stock

Is CDIO stock a buy right now?

Of the 1 analysts covering Cardio Diagnostics Holdings, Inc., 1 rate it a Buy, 0 a Hold and 0 a Sell. Ticker Nerd's systematic factor model ranks Cardio Diagnostics Holdings, Inc. 20 out of 100 across roughly 4,600 US stocks as at 14 Sept 2026. None of this is personal advice — it does not consider your circumstances.

How does Ticker Nerd's model rank CDIO?

As at 14 Sept 2026, Cardio Diagnostics Holdings, Inc. ranks 20 out of 100 on Ticker Nerd's systematic factor model — a percentile across roughly 4,600 US stocks, built from its factor families. Its strongest factor family is Size (95 of 100).

What is the CDIO stock forecast for 2030?

No analyst covering Cardio Diagnostics Holdings, Inc. publishes a 2030 price target — Wall Street targets run 12 to 18 months out. Sites quoting a 2030 price for CDIO are extrapolating price history, which says nothing about the business.

How has CDIO stock performed over the past year?

Cardio Diagnostics Holdings, Inc. returned -46.7% over the 12 months to 15 Sept 2026, with dividends reinvested. Past performance does not indicate future returns.

What does Cardio Diagnostics Holdings, Inc. do?

Cardio Diagnostics Holdings, Inc. is a medical technology company focused on developing and commercializing epigenetics-based clinical tests for cardiovascular disease.

What is the latest news on CDIO?

The most recent item we track (Business Wire, 26 Aug 2026): "Cardio Diagnostics Report Identifies Growing Rural Cardiovascular Care Gap Amid Ongoing Workforce Shortages and Access Challenges". Cardio Diagnostics released a new edition of its rural health report, "The State of Rural Hospitals and Cardiovascular Care," which identifies a growing cardiovascular care gap in rural areas amid ongoing workforce shortages and access challenges. The company announced the report release via Business Wire from Chicago.

Company

About Cardio Diagnostics Holdings, Inc.

Cardio Diagnostics Holdings, Inc. is a medical technology company focused on developing and commercializing epigenetics-based clinical tests for cardiovascular disease. The company’s current offerings include blood-based diagnostics for coronary heart disease risk assessment and early detection, supported by AI-driven analysis of genetic and epigenetic biomarkers. Cardio Diagnostics also provides tools and platforms that help clinicians interpret cardiovascular risk and support research and development use in biopharmaceutical and medical settings. Its products are designed to improve the assessment, detection, and management of cardiovascular conditions such as coronary heart disease and related comorbidities through more precise clinical insights. Based in Chicago, Illinois, Cardio Diagnostics Holdings serves the growing market for advanced cardiovascular diagnostics and precision medicine.

CEO Dr. Meeshanthini V. Dogan Ph.D. · 15 employees · United States · https://cdio.ai